Scinai Immunotherapeutics Ltd - ADR
SCNI
Get informed when a big investor buys or sells
+ FollowMarket Cap$858.12K
Close$
$1.67
31.7% downside
Current Fair Value
31.7% downsideOvervalued by 31.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $858,117.00 |
|---|---|
| Enterprise Value | $1.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-36 |
| Beta | 2.08 |
| Outstanding Shares | 57,002,218 |
Return
| Return on Equity | -26.94% |
|---|---|
| Return on Assets | -18.41% |
| Return on Invested Capital | -63.69% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.06 |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.26 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-8.50
Average shareholder expectationRevenue Estimate
$494,553
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Scinai Immunotherapeutics Ltd
26 employees
CEO: Ron Babecoff biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and p...